Intensity-controlled Raster Scanning Carbon Ion Radiation Therapy With a Heavy-ion Gantry: Clinical Experience at Heidelberg Ion Beam Therapy Center
PURPOSE: Carbon ions have biophysical advantages over photons, including a finite range, increased relative biological effectiveness, and lowered oxygen dependence. Maximum treatment flexibility is attainable with rotational beam delivery. We report our clinical experience using the carbon-ion gantry at the Heidelberg Ion Beam Therapy Center with intensity-controlled raster scanning capability, focusing on treatment toxicity. METHODS AND MATERIALS: A total of 1622 patients treated using the carbon-ion gantry between 2012 and 2026 were evaluated. Data were analyzed using descriptive statistics. Toxicity analysis was conducted using Common Terminology Criteria of Adverse Events v5.0. RESULTS: The median age preradiation therapy was 59 years (range, 18-91). Most patients had locally advanced tumors (21.8% T4; 11.2% T3) without regional lymph node metastases (45.4% N0). The most common treatment indications were sacrococcygeal tumors (n = 331; 20.4%), followed by tumors of the paranasal sinuses (n = 166; 10.2%) and the spine (n = 121; 7.5%). A total of 486 patients (30.0%) received carbon-ion reirradiation, the most frequent carbon-ion gantry treatment indication viewed across all patients. The most common particle therapy beam-angle number was 2 (range, 1-7). The use of more than 2 beam angles was particularly frequent in tumors of the skull base (45.8%) and the thoracic region (40.0%). High-grade (III and IV) acute and late toxicity rates were 2.4% and 4.2% in primary treatment. Mean numbers of acute and late grade I and II toxicity events per patient were 2.2 (95% confidence interval, 2.0-2.4) and 2.0 (95% confidence interval, 1.7-2.4), respectively. CONCLUSIONS: Carbon-ion radiation therapy using a heavy-ion gantry resulted in favorable toxicity rates in specific indications. Further interdisciplinary research demonstrating the clinical benefit of carbon-ion radiation therapy is required. This study provides more evidence supporting particle therapy facilities and may serve as a foundation for prospective clinical trials.
Authors
- Semi Harrabi (ORCID: https://orcid.org/0000-0003-1195-7150)
- Stella Winter
- Henrik Franke
- Thomas Held (ORCID: https://orcid.org/0000-0002-3913-4693)
- Malte Ellerbrock (ORCID: https://orcid.org/0000-0002-4086-0908)
- Klaus K Herfarth (ORCID: https://orcid.org/0000-0002-6325-4193)
- Sebastian Adeberg (ORCID: https://orcid.org/0000-0001-8463-514X)
- Cihangir Çakır
- Andrea Mairani (ORCID: https://orcid.org/0000-0001-6669-7064)
- Katharina Dvornikovich
- Thomas Haberer
- Marcus Winter
- Jürgen Debus
- Mia Sittinger
- Ziqi Cathy Jiang
- Leonhard Dörsam
- Till Manzey
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- Heidelberger Institut für Radioonkologie (DE)
- National Center for Tumor Diseases (DE)
Publication Details
- Journal
- International Journal of Radiation Oncology*Biology*Physics
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1016/j.ijrobp.2026.09.003
- Primary Topic
- Radiation Therapy and Dosimetry
- Type
- article
- Field-Weighted Citation Impact
- 0.00